Eisai Co Ltd from Japan/US is one of our rivals/competitors.
Here is our potential, when we get a slice of the pie you will scoff at current Share price levels. They took a front door approach through Japan and the US. We are taking the Russian/ Australian back door route. We needed to protect our brands, patents and stopped newsletters to maintain our competitive advantage.
Too much info was going in newsletters/publications for rivals to diseminate and try to copy. We had to protect and hold our, research, scientists, patents, etc. More will be revealed as per trial updates on Wednesday night the 3rd of September.
http://www.eisai.com/
Eisai Inc. (pronounced ā-zī) is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2.6 billion in fiscal year 2006 (year ending March 31, 2007).
Eisai Co., Ltd., a research-based pharmaceutical company, engages in the manufacture and marketing of pharmaceutical drugs, over-the-counter drugs, and ph armaceuticals production systems and equipments worldwide. It sells prescription pharmaceuticals that include Aricept for the treat ment of mild-to-moderate Alzheimer s disease; and Cleactor for the treatment of pulmonary embolism. The company is also developing products in the therapeutic areas of neurology, gastroenterology, oncology, and locomotory system, as well as drugs for the tr eatment of paroxysmal atrial fibril lation, flutter, and acute coronary syndrome. It offers consumer health care products, such as medicated skin care cream, and tablets for stomach heaviness, heartburn, overeat ing, and rhinitis, as well as vitamin B# supplements; and diagnostics for the detection of microalbumin, monitoring liver functions and blood coagulation activities, and determination of antigalactosyl IgG antibodies, IgG rheum atoid...
SLA Price at posting:
0.0¢ Sentiment: ST Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)